Form D · Biotechnology
PD Theranostics, Inc.
New York, NY · CIK 0001830286
Offering snapshot reported Dec 14, 2023 · SEC filing
- Reported sold
- $150K Offering amount: $1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 12, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 14, 2023 | Initial | $150,000 | No comparison | 2 | SEC filing |
| Jul 28, 2022 | Initial | $358,165 | No comparison | 3 | SEC filing |
| Jul 28, 2022 | Amendment | $358,165 | $0vs Jul 28, 2022 | 3 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $15K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-499738
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Laidlaw & Company (UK) Ltd. | 119037 |
Source: Form D, filed Dec 14, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Ahern | Director |
| Matthew Duffy | Director, Executive |
| Matthew Eitner | Director |
| Patrick Gallagher | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12 E 49 Th Street 11 Th Floor
New York, NY, 10017
New York, NY, 10017